KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Issued (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Shares Issued readings, the most recent being $657000.0 for Q4 2025.

  • On a quarterly basis, Shares Issued rose 212.12% to $657000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $9.1 million, a 164.66% increase, with the full-year FY2025 number at $9.1 million, up 164.66% from a year prior.
  • Shares Issued hit $657000.0 in Q4 2025 for Biocryst Pharmaceuticals, down from $2.6 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $37.8 million in Q4 2021 to a low of -$586000.0 in Q4 2024.
  • Median Shares Issued over the past 5 years was $2.5 million (2025), compared with a mean of $4.3 million.
  • Biggest five-year swings in Shares Issued: skyrocketed 1204.92% in 2021 and later crashed 1602.56% in 2024.
  • Biocryst Pharmaceuticals' Shares Issued stood at $37.8 million in 2021, then crashed by 89.38% to $4.0 million in 2022, then plummeted by 99.03% to $39000.0 in 2023, then crashed by 1602.56% to -$586000.0 in 2024, then soared by 212.12% to $657000.0 in 2025.
  • The last three reported values for Shares Issued were $657000.0 (Q4 2025), $2.6 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.